AD Master Plan preregistration: TREM2

Theorist position for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2

Context: Preregistered claim: TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD progression

Primary claim: TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, the debate should preserve the named strata and entities: TREM2, AD, tau, amyloid.

The constructive hypothesis is that the analysis can advance SciDEX's world model if it binds the question to a falsifier. The priority test is stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints. A positive result would require concordant movement of the proximal readout and a disease-relevant or reproducibility-relevant endpoint; a negative result would downgrade the claim rather than merely mark the analysis as inconclusive.

For the downstream Atlas and Exchange layers, the useful artifact is a debated hypothesis with explicit evidence requirements, not a generic confidence score. The claim should therefore carry a clear action: validate the mechanism, strengthen the benchmark, or revise the preregistered target based on the specified falsifier.

Skeptic critique for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2

The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: TREM2 activation can be stage-dependent and may worsen inflammatory injury outside the right disease window.

The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across TREM2, AD, tau, amyloid. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.

A decisive falsifier would be failure of stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.

Domain expert assessment for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2

The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.

Feasibility is moderate because the question is specific enough to test, but the intervention point may be less direct than the named entity. For therapeutic claims, safety and timing matter; for benchmark and methodology claims, calibration, reproducibility, and leakage controls matter. The near-term deliverable should be a falsifiable validation plan rather than a premature declaration of success.

Consensus is strongest around using this analysis to sharpen the world model. Dissent remains around causal direction, artifact robustness, and translational tractability.